Mitochondrial permeability in neuronal death: Possible relevance to the pathogenesis of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 5, Issue 4, 1999, Pages 221-229

  Tatton, W G ^a   Chalmers Redman, R M E ^a   Rideout, H J ^a   Tatton, N A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 1 Methyl 4 phenylpyridinium; Apoptosis; Mitochondrial membrane potential; Mitochondrial permeability transition pore; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

APOPTOSIS; DOPAMINERGIC NERVE CELL; HEREDITY; HUMAN; HUMAN CELL; LEWY BODY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NECROSIS; PARKINSONISM; PATHOGENESIS; PERMEABILITY; PRIORITY JOURNAL; REVIEW;

EID: 0032866289     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00041-3     Document Type: Article

References (112)

1. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 22:1999;123-144.
2. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol. 401:(2):1998;253-265.
3. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 114:(Pt 5):1991;2283-2301.
4. Wang Y., Chan G.L., Holden J.E., Dobko T., Mak E., Schulzer M., et al. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse. 30:(1):1998;56-61.
5. Anglade P., Vyas S., Hirsch E.C., Agid Y. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol. 12:(3):1997;603-610.
6. Tompkins M.M., Basgall E.J., Zamrini E., Hill W.D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigra neurons. Am J Pathol. 150:(1):1997;119-131.
7. Pakkenberg B., Moller A., Gundersen H.J., Mouritzen Dam A., Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 54:(1):1991;30-33.
8. Ma S.Y., Rinne J.O., Collan Y., Roytta M., Rinne U.K. A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J Neurol Sci. 140:(1/2):1996;40-45.
9. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol. 34:(3):1993;331-338.
10. Vingerhoets F.J., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission to tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 36:(5):1994;765-770.
11. 18F] dopa PET. J Neurol Neurosurg Psychiatry. 64:(3):1998;314-319.
12. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann Neurol. 44:(3(Suppl 1)):1998;S72-S84.
13. Tanner C.M., Ottman R., Goldman S.M., Ellenberg J., Chan P., Mayeux R., et al. Parkinson's disease in twins: an etiologic study. Jama. 281:(4):1999;341-346.
14. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:(5321):1997;2045-2047.
15. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 18:(2):1998;106-108.
16. Vaughan J., Durr A., Tassin J., Bereznai B., Gasser T., Bonifati V., et al. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. Ann Neurol. 44:(2):1998;270-273.
17. Gasser T., Muller-Myhsok B., Wszolek Z.K., Oehlmann R., Calne D.B., Bonifati V., et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Gent. 18:(3):1998;262-265.
18. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:(4587):1983;979-980.
19. Langston J.W., Langston E.B., Irwin I. MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects. Acta Neurol Scand Suppl. 100:1984;49-54.
20. Burns R.S., Markey S.P., Phillips J.M., Chiueh C.C. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci. 11:(Suppl 1):1984;166-168.
21. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292:(2):1984;390-394.
22. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol. 20:(4):1986;449-455.
23. Crossman A.R., Clarke C.E., Boyce S., Robertson R.G., Sambrook M.A. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci. 14:(Suppl 3):1987;428-435.
24. Miyoshi R., Kito S., Ishida H., Katayama S. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism. Res Commun Chem Pathol Pharmacol. 62:(1):1988;93-102.
25. Pifl C., Schingnitz G., Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett. 92:(2):1988;228-233.
26. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic tertiary amine MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 129:(2):1984;574-578.
27. +, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun. 128:(3):1985;1228-1232.
28. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:(26):1985;2503-2508.
29. +, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys. 259:(2):1987;645-649.
30. + inhibit activity of mitochondrial NADH-ubiquinone oxidoreductase. Proc Jpn Acad, Ser B: Phys Biol Sci. 62:(7):1986;261-263.
31. Mizuno Y., Saitoh T., Sone N. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun. 143:(3):1987;971-976.
32. +) cause rapid ATP depletion in isolated hepatocytes. Biochem Biophys Res Commun. 137:(1):1986;310-315.
33. + on endogenous dopamine release from the rat corpus striatum superfused in vitro. Brain Res. 368:(1):1986;134-140.
34. +. Free Radic Biol Med. 13:(5):1992;581-583.
35. Chiueh C.C., Wu R.M., Mohanakumar K.P., Sternberger L.M., Krishna G., Obata T., et al. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann NY Acad Sci. 738:1994;25-36.
36. +: implications for neurodegeneration. J Neurochem. 63:(2):1994;584-591.
37. Fernandez-Checa J.C., Garcia-Ruiz C., Colell A., Morales A., Mari M., Miranda M., et al. Oxidative stress: role of mitochondria and protection by glutathione. Biofactors. 8:(1/2):1998;7-11.
38. +(1-methyl-4-phenylpyridinium) in rat and mouse. Brain Res. 461:(2):1988;361-366.
39. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:(3):1995;257-269.
40. Tatton W.G., Olanow C.W. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim Biophys Acta Bioenergetics. 1410:(2):1999;195-213.
41. McGeer P.L., McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord. 12:(Suppl 2):1998;S1-S6.
42. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord. 13:(Suppl 1):1998;24-34.
43. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 54:(3):1990;823-827.
44. Schapira A.H., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 55:(6):1990;2142-2145.
45. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Comm. 163:1989;1450-1455.
46. Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., Ikebe S. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol. 35:(2):1994;204-210.
47. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 40:(4):1996;663-671.
48. Spooren W.P.J.M., Gentsch C., Wiessner C. Tunel-positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 85:(2):1998;649-651.
49. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 77:(4):1997;1037-1048.
50. Desole M.S., Sciola L., Delogu M.R., Sircana S., Migheli R. Manganese and 1-methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine induce apoptosis in PC12 cells. Neurosci Lett. 209:(3):1996;193-196.
51. +) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma SH-SY5Y cells, through different mechanisms. Brain Res. 704:(2):1995;240-245.
52. +)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett. 224:(3):1997;197-200. published erratum appeared in Neurosci Lett, 1997 30;228(1):67.
53. + induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study. J Neurosci Res. 48:(3):1997;226-237.
54. Seaton T.A., Cooper J.M., Schapira A.H. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777:(1-2):1997;110-118.
55. +)-induced cytotoxicity in human neuroblastoma SH-SY5Y. J Toxicol Sci. 23:1998;184-188. Suppl 2.
56. Leist M., Volbracht C., Fava E., Nicotera P. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol Pharmacol. 54:(5):1998;789-801.
57. Kitamura Y., Kosaka T., Kakimura J.I., Matsuoka Y., Kohno Y., Nomura Y., et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 54:(6):1998;1046-1054.
58. Saporito M.S., Brown E.M., Miller M.S., Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther. 288:(2):1999;421-427.
59. +-induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res. 55:(5):1999;620-628.
60. +-induced apoptosis depends on mitochondrial membrane potential and ATP synthase. Biochem Biophys Res Comm. 257:(2):1999;440-447.
61. Seaton T.A., Cooper J.M., Schapira A.H.V. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res. 809:(1):1998;12-17.
62. Dipasquale B., Marini A.M., Youle R.J. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem Biophys Res Commun. 181:(3):1991;1442-1448.
63. +) in ventral mesencephalic-striatal co-culture in rat. Neurosci Lett. 170:(1):1994;191-194.
64. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci. 137:(2):1996;120-123.
65. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol. 12:(1):1997;25-31.
66. Hirsch E.C., Hunot S., Faucheux B., Agid Y., Mizuno Y., Mochizuki H., et al. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov Disord. 14:(2):1999;383-385.
67. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol. 44:(3):1998;S142-S148. Suppl 1.
68. Tatton N.A., Rideout H.J. Confocal microscopy as a tool to examine DNA fragmentation, chromatin condensation and other apoptotic changes in Parkinson's Disease. Parkinsonism Rel Disorders. 5:(4):1999;000.
69. Tatton W.G., Chalmers-Redman R.M., Ju W.Y., Wadia J., Tatton N.A. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm Suppl. 49:1997;245-268.
70. Kroemer G., Petit P., Xamzami N., Vayssierre J.L., Mignotte B. The biochemistry of programmed cell death. Faseb. 9:1995;1277-1287.
71. Susin S.A., Zamzami N., Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta Bioenergetics. 1336:(1-2):1998;151-165.
72. Kroemer G., Zamzami N., Susin S.A. Mitochondrial control of apoptosis. Immunol Today. 18:(1):1997;44-51.
73. Tatton W.G., Chalmers-Redman R.M. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? Ann Neurol. 44:(3(Suppl 1)):1998;S134-S141.
74. Neupert W. Protein import into mitochondria. Annu Rev Biochem. 66:1997;863-917.
75. Rabinovitz Y.M., Pinus H.A., Kotelnikova A.V. A study of dependence of protein synthesis in mitochondria on the transmembrane potential. Mol Cell Biochem. 14:(1/3):1977;109-113.
76. Yang J.C., Cortopassi G.A. Induction of the mitochondrial permeability transition causes release of the apoptogenic factor cytochrome c. Free Radic Biol Med. 24:(4):1998;624-631.
77. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Brenner C., Larochette N., et al. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med. 189:(2):1999;381-394.
78. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 397:1999;441-446.
79. Gorman A.M., Bonfoco E., Zhivotovsky B., Orrenius S., Ceccatelli S. Cytochrome c release and caspase-3 activation during colchicine-induced apoptosis of cerebellar granule cells. Eur J Neurosci. 11:(3):1999;1067-1072.
80. Pan G., Humke E.W., Dixit V.M. Activation of caspases triggered by cytochrome c in vitro. FEBS Lett. 426:(1):1998;151-154. published erratum appeared in FEBS Lett, 1998 29;428(3):309].
81. Stridh H., Kimland M., Jones D.P., Orrenius S., Hampton M.B. Cytochrome c release and caspase activation in hydrogen peroxide- and tributyltin-induced apoptosis. FEBS Lett. 429:(3):1998;351-355.
82. Bossy-Wetzel E., Newmeyer D.D., Green D.R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. Embo J. 17:(1):1998;37-49.
83. Brustugun O.T., Fladmark K.E., So Ds., Orrenius S., Zhivotovsky B. Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2. Cell Death Differ. 5:(8):1998;660-668.
84. Liu X.S., Zou H., Slaughter C., Wang X.D. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 89:(2):1997;175-184.
85. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Ngata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50.
86. Marzo I., Brenner C., Kroemer G. The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes. Biomedi Pharmacother. 52:(6):1998;248-251.
87. Zamzami N., Brenner C., Marzo I., Susin S.A., Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene. 16:(17):1998;2265-2282.
88. Marzo I., Brenner C., Zamzami N., Jurgensmeier J.M., Susin S.A., Vieira H.L.A., et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 281:(5385):1998;2027-2031.
89. Scorrano L., Petronilli V., Bernardi P. On the voltage dependence of the mitochondrial permeability transition pore - a critical appraisal. J Biol Chem. 272:(19):1997;12 295-12 299.
90. Allen R.T., Cluck M.W., Agrawal D.K., et al. Mechanisms controlling cellular suicide: role of Bcl-2 and caspases. Cell Mol Life Sci. 54:(5):1998;427-445.
91. Marzo I., Brenner C., Zamzami N., Susin S.A., Beutner G., Brdiczka D. The permeability transition pore complex: A target for apoptosis regulation by caspases and Bcl-2-related proteins. J Exp Med. 187:(8):1998;1261-1271.
92. Nunez G., Benedict M.A., Hu Y., Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 17:(25):1998;3237-3245.
93. Bernardi P. The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim Biophys Acta. 1275:(1-2):1996;5-9.
94. Zamzami N., Marchetti P., Castedo M., Hirsch T., Susin S.A., Masse B., et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett. 384:(1):1996;53-57.
95. Nieminen A.L., Petrie T.G., Lemasters J.J., Selman W.R. Cyclosporin A delays mitochondrial depolarization induced by N-methyl-D-aspartate in cortical neurons: evidence of the mitochondrial permeability transition. Neuroscience. 75:(4):1996;993-997.
96. Cassarino D.S., Swerdlow R.H., Parks J.K., Parker W.D. Jr, Bennett J.P. Jr. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun. 248:(1):1998;168-173.
97. Walter D.H., Haendeler J., Galle J., Zeiher A.M., Dimmeler S. Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome c from mitochondria. Circulation. 98:(12):1998;1153-1157.
98. Hortelano S., Dallaporta B., Zamzami N., Hirsch T., Susin S.A., Marzo I., et al. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Lett. 410:(2-3):1997;373-377.
99. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta. 1453:(1):1998;49-62.
100. Yang L., Matthews R.T., Schulz J.B., Klockgether T., Liao A.W., Martinou J.C., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci. 18:(20):1998;8145-8152.
101. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G.U. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem. 59:(2):1992;733-739.
102. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:(6308):1991;414-418. see comments.
103. Tabatabaei A., Perry T.L., Hansen S., Krieger C. Partial protective effect of MK-801on MPTP-induced reduction of striatal dopamine in mice. Neurosci Lett. 141:(2):1992;192-194.
104. +) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol Aging. 14:(4):1993;295-301.
105. Sonsalla P.K., Zeevalk G.D., Manzino L., Giovanni A., Nicklas W.J. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem. 58:(5):1992;1979-1982.
106. +) in rat dissociated mesencephalic cultures. Brain Res. 597:(2):1992;233-240.
107. Kupsch A., Loschmann P.A., Sauer H., Arnold G., Renner P., Pufal D. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 592:(1-2):1992;74-83.
108. Wadia J.S., Chalmers-Redman R.M.E., Ju W.J.H., Carlile G.W., Phillips J.L., Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis caused by trophic withdrawal: time course and modification by (-)-deprenyl. J Neurosci. 18:1998;932-947.
109. Choi D.W., Hartley D.M. Calcium and glutamate-induced cortical neuronal death. Res Publ Assoc Res Nerv Ment Dis. 71:1993;23-34.
110. Basma A.N., Heikkila R.E., Saporito M.S., Philbert M., Geller H.M., Nicklas W.J. 1-Methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells is enhanced by preventing glycolysis. J Neurochem. 58:(3):1992;1052-1059.
111. DiMonte D., Sandy M.S., Blank L., Smith M.T. Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes. Biochem Biophys Res Commun. 153:(2):1988;734-740.
112. Marchetti P., Susin S.A., Decaudin D., Gamen S., Castedo M., Hirsch T., et al. Apoptosis associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res. 56:(9):1996;2033-2038.